ESElena Vitalyevna Sayutina

Elena Vitalyevna Sayutina

*This is an algorithmically generated author record based on publicly available information.

Elena Vitalyevna Sayutina has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiac rehabilitation and secondary prevention after acute myocardial infarction: a modern view on the problem

    by Elena V. Sayutina, Mikhail A. Osadchuk, Boris K. Romanov, Elena M. Tuaeva, Ludmila I. Butorova, Gyulnara O. Dibirova, Natalya V. Kireeva, Nikolay P. Korzhenkov

    Cardiovascular diseases remain a heavy socioeconomic burden in the modern world, claiming up to four million lives annually, including one million of the Russian population. Most often, cardiovascular mortality is associated with chronic coronary heart disease and its complications. Despite the progress in the treatment of acute coronary syndrome in the acute disease phase, the problem of recurrent coronary events and associated adequate rehabilitation remains unresolved. Modern Russian and European recommendations for cardiovascular rehabilitation present the main directions of secondary prevention of myocardial infarction, which summarize the global and Russian evidence-based medicine data on the problem and are based on the principles of phasing, continuity, succession, and multidisciplinary approach to the patient management. This review focuses on the problems and shortcomings of secondary prevention and cardiac rehabilitation at the patient, doctor, and healthcare system levels. In addition, contemporary approaches to their elimination are described. The necessity and importance of individual training and informing patients and the formation of their sustainable commitment to a healthy lifestyle and therapeutic and preventive measures prescribed by modern guidelines on this issue are emphasized.


  • Open Access

    Place of renin-angiotensin-aldosterone system inhibitors and statins in the treatment of cardiovascular patients in the context of COVID-19 pandemic

    by E. V. Sayutina, L. I. Butorova, E. M. Tuaeva, M. A. Osadchuk, M. M. Shamuilova

    Patients at high cardiovascular risk, older people with cardiovascular comorbidities, as well as those with hypertension and familial hypercholesterolemia are more susceptible to severe coronavirus disease 2019 (COVID-19). Such patients are likely to be at increased long-term atherothrombotic risk after COVID-19. The renin-angiotensinaldosterone system (RAAS) not only plays a key role in the development and progression of cardiovascular diseases, but is also responsible for the penetration of the Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) into the cells of target organs and the development of infection. Given that RAAS inhibitors and statins increase the expression of angiotensin-converting enzyme type 2 receptors, concerns were initially raised about their possible adverse effect on COVID-19 course. However, at present, we have data from large-scale, including randomized clinical trials and meta-analyses, confirming the organ protective effects of RAAS inhibitors and statins by reducing the inflammation severity and fibrosis in tissues. The review attempted to assess the potential role of these drugs in the management of SARS-CoV-2-infected patients and their impact on the development of complications.

  • THE ROLE OF PROKINETICS IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE

    by L. Butorova, L. Konkova, V. Levin, N. Nugaeva, M. Palchenkova, E. Sayutina


  • Clinical Pharmacology

    by Irina Veniaminovna Andreeva, Andrey Igorevich Danilov, Lyudmila Pavlovna Zharkova, Roman Sergeyevich Kozlov, Sergey Nikolaevich Kozlov, Elena Vitalyevna Khaykina, Olga Ulianovna Stetsyuk, Arkady Lvovich Vertkin, Elena Adamovna Prokhorovich, Marina Miirovna Shamuilova, et al.

  • Open Access

    Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy

    by Maria D. Ardatskaya, Ludmila I. Butorova, Marina A. Kalashnikova, Nelli R. Nugaeva, Yury V. Ovchinnikov, Olga S. Oynotkinova, Aleksandr I. Pavlov, Roman G. Plavnik, Elena V. Sayutina, Tatiana В. Topchiy, et al.

    Background. The novel coronavirus infection COVID-19 can be manifested by damage to the organs of the gastrointestinal tract (GIT). Damage to the gastrointestinal tract by the SARS-CoV-2 virus leads to a violation of the microbial-tissue complex of the mucous membrane of the digestive tract. A common gastroenterological manifestation of COVID-19 is diarrhea. Aim. Study of the clinical features of gastroenterological disorders and the possibility of optimizing the treatment of diarrheal syndrome in patients with COVID-19 with a mild form of viral infection. Materials and methods. The observation group consisted of 230 patients with mild COVID-19: K-group (n=115) with respiratory symptoms, I group (n=115) with gastrointestinal manifestations in combination and without signs of respiratory damage. In order to compare the effectiveness of treatment of diarrheal syndrome, patients of group I are randomized into 2 subgroups: Ia (n=58) prebiotic treatment (Zacofalk) and Ib (n=57) enterosorbents. Results. The development of gastrointestinal symptoms with SARS-CoV-2 infection is significantly more often noted in comorbid patients (67%). Gastrointestinal symptoms were dominated by diarrhea (93.9%) and flatulence (76.5%), in 1/3 of patients they were the first manifestos of infection. It was established that in 98.4% of patients of group I (against 42.6% of the K-group) signs of infectious intoxication were detected. In patients with gastrointestinal lesions, an elongation of the febrile period by 91.5 days was noted, a later (6 days) verification of the viral etiology of the disease. It was found that in patients of group I, the regression of clinical symptoms, the duration of viral disease, the dynamics of antibody formation, the prognosis for the development of IBS-like disorders in the post-infectious period depended on the treatment. In patients taking (Zacofalk), these indicators were significantly better. Conclusion. In mild cases, to reduce the severity of viral intestinal damage, for effective relief of intestinal symptoms, to reduce the risk of IBS-like symptoms, it is advisable to prescribe (Zacofalk) in an initial dose of 3 tablets per day.


  • Open Access

    Statin therapy in patients with high and very high cardiovascular risk: an optimal approach

    by E. V. Sayutina, M. M. Shamuilova, L. I. Butorova, E. M. Tuayeva, A. L. Vertkin

    Статинотерапия у пациентов высокого и очень высокого сердечно-сосудистого риска: оптимальный подход


  • Statin therapy in patients with high and very high cardiovascular risk: an optimal approach

    by E. V. Sayutina, M. M. Shamuilova, L. I. Butorova, E. M. Tuayeva, A. L. Vertkin

  • Open Access

    Comparative effectiveness of ursodeoxycholic acid preparations in the treatment of biliary sludge

    by L. I. Butorova, M. D. Ardatskaya, M. A. Osadchuk, A. E. Drobysheva, E. A. Zagrebina, N. G. Kadnikova, M. A. Kalashnikova, E. I. Lukianova, L. N. Pavlova, R. G. Plavnik, et al.

    In the clinical classification of cholelithiasis, biliary sludge (BS) is distinguished as the pre-stone stage. Ursodeoxycholic acid (UDCA) is a drug with an evidence base for effective and safe effects on BS. The therapeutic equivalence of various UDCA drugs remains an important issue for clinical practice. Aim. To conduct a comparative analysis of the effectiveness of the use of UDCA: Ursofalk with other UDCA drugs for the treatment of BS in a fixed dose of 10 mg/kg of body weight. Material and methods. The observation group consisted of 225 patients with various types of BS. In randomized groups, the comparison of the effectiveness of UDCA drugs in the dissolution of BS was determined by the data of ultrasound of the gallbladder. Dynamic ultrasound cholecystography using a standardized technique was performed to study the effect of the compared drugs on the contractile function of the liver. When analyzing the impact of ursotherapy on the clinical manifestations of BS, the dynamics of biliary pain syndrome and dyspeptic disorders were evaluated. Results. A comparative analysis of the effectiveness of UDCA drugs for BS lysis with a high degree of confidence established the advantage of Ursofalk: after 3 months in 80%, and after 6 months of therapy in 95.65% of patients, a regression of BS was detected. In the group of patients who took other UDCA, the corresponding indicators were 46.36% and 67.27%. The greatest effectiveness of ursotherapy was demonstrated in the BS variant by the type of suspension of hyperechogenic particles, the lowest in the variant by the type of putty-like bile in the form of mobile or fixed clots. In the last variant of BS, the relationship between the success of lysis with the extension of the UDCA intake period to 6 months and the preferred choice of Ursofalk was traced. Normalization of the contractile function of the gallbladder was noted in patients who took Ursofalk. Conclusion. From the standpoint of therapeutic effectiveness, the drug of choice for the treatment of BS, regardless of its type, is Ursofalk, which has proven the best dynamics of BS litolysis, recovery of the contractile function of the gastrointestinal tract, and relief of clinical symptoms.


  • Open Access

    Comparison of clinical-metabolic efficacy of pre- and probiotics in the conducted optimized protocols of eradication therapy of Helicobacter pylori infection

    by L. I. Butorova, M. D. Ardatskaya, M. A. Osadchuk, N. G. Kadnikova, E. I. Lukianova, R. G. Plavnik, E. V. Sayutina, T. B. Topchiy, E. M. Tuayeva, Лукьянова Елена Ивановна, et al.

    Low patient compliance due to the development of adverse events in the form of antibiotic-associated diarrhea (AAD) is considered as the main reason for the failure of the eradication of optimized anti-Helicobacter therapy regimens. A key mechanism for the development of AAD is to reduce the number and species diversity of bacteria that form butyric acid. Aim. The purpose of this study was to study the comparative effect on the clinical effectiveness of eradication therapy (ET) of Helicobacter pylori infection and metabolic changes in the colon microbiota of additional inclusion in the optimized treatment regimen of the combined prebiotic Zakofalk (inulin + butyrate) with probiotics (lacto- and bifidobacteria in an amount of at least 1017 СFU). Materials and methods. 120 patients with chronic gastroduodenal diseases and infected H. pylori were еxamined. A comparative analysis of the effect of a combined prebiotic and lacto-bifid-containing probiotics on improving the effectiveness of the optimized ET scheme and improving its tolerability, as well as on the quantitative and qualitative content of short-chain fatty acids (SFA) in feces. The success of eradication was controlled by a 13C urease breath test. Results. According to the results of the study in randomized groups of patients, an excellent percentage of eradication (95%) was achieved in patients who performed ET with the addition of the prebiotic Zakofalk. In the same group of patients, there was an increase in the absolute content of SFA and a significant increase in the concentration of butyric acid. In the group of patients who received ET with the addition of probiotics, an acceptable level of eradication was achieved (85.7%), but no changes in SFA were found indicating an increase in the number or activity of the butyrate-producing flora. Patients who performed ET without the addition of pre-probiotics did not achieve the target percentage of successful eradication (83.3%), and a significant quantitative decrease in SFA was found with a significant decrease in the proportion of butyric acid. Conclusion. The inclusion of Zakofalk in the ET scheme, in comparison with probiotics, significantly increases the probability of successful eradication, more effectively restores the metabolic potential of the microbiota, and prevents the development of AAD.


  • Open Access

    Telmisartan in the hypertension treatment: from pharmacological characteristics to clinical benefits

    by E. V. Sayutina, L. I. Butorova, E. M. Tuaeva, M. A. Osadchuk

    Телмисартан в комплексной терапии артериальной гипертензии: от фармакологических особенностей к клиническим преимуществам